ImpediMed earns Frost & Sullivan 2025 Technology Innovation Leadership Award
This award has been for ImpediMed's support in the Point-of-Care Bioimpedance Spectroscopy Industry
21 Jan 2025
ImpediMed has announced that it has been awarded the Frost & Sullivan 2025 North American Technology Innovation Leadership Award in the Point-of-Care Bioimpedance Spectroscopy Industry. The award recognizes ImpediMed's commitment to improving long-term patient outcomes through its SOZO® Digital Health Platform, a non-invasive bioimpedance spectroscopy (BIS) solution to address unmet healthcare needs through fluid and body composition point-of-care patient monitoring, particularly in breast cancer-related lymphedema (BCRL).
As a supporter in the field of lymphedema detection and monitoring, ImpediMed offers the only FDA-cleared BIS technology for the clinical assessment of BCRL supported by a large randomized clinical trial and multiple clinical practice guidelines.
BIS provides a non-invasive, quick, and highly sensitive method for detecting fluid changes in the body. By sending a small electrical current through the body to measure resistance, BIS can identify subclinical lymphedema long before visible symptoms appear.
A landmark clinical trial has demonstrated the effectiveness of ImpediMed's BIS technology in preventing chronic lymphedema among breast cancer patients. The PREVENT trial, tracking over 1,200 patients across U.S. and Australian healthcare facilities, showed that early detection using BIS technology prevented progression to chronic lymphedema in 92% of cases. These results validate SOZO's potential as a standard preventive screening tool in oncology clinics worldwide.
"ImpediMed's bioimpedance spectroscopy solution differentiates fluid types with high precision, offering an L-Dex® score to detect early changes in the fluid for clinical intervention in breast cancer-related lymphedema, body composition to measure muscle and fat loss, and HF-Dex to support the management of heart failure," said Isai Pratha Karthik Ph.D., Senior Research Analyst with Frost & Sullivan. "This precision is due to ImpediMed's refined approach to measure impedance at 256 different frequencies up to 1,000 KHz. These accurate measurements provide a comprehensive view of fluid and tissue composition and help clinicians make efficient, data-driven decisions."
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>